Journal ArticleOPEN ACCESS

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

  • Motzer R
  • Alekseev B
  • Rha S
  • et al.
New England Journal of Medicine (2021) 384(14) 1289-1300
DOI: 10.1056/nejmoa2035716
1.6kCitations
Citations of this article
661Readers
Mendeley users who have this article in their library.

Abstract

Abstract Background Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib ...

Cite

CITATION STYLE

APA

Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., … Choueiri, T. K. (2021). Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 384(14), 1289–1300. https://doi.org/10.1056/nejmoa2035716

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free